Market Overview

Senseonics Begins U.S. Commercialization of Eversense Continuous Glucose Monitoring System With First Shipment, First Users and First Policy Coverage

Share:

Trained and authorized U.S. diabetes clinics begin providing the
first-ever 90-day, long-term CGM system to people with diabetes

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology
company focused on the development and commercialization of a long-term,
implantable continuous glucose monitoring (CGM) system for people with
diabetes, today announced that the Eversense® CGM System is now
available at trained clinics across the U.S. and physicians have begun
sensor placements with patients. Concurrently, the company reported that
its first commercial payer, Horizon Blue Cross Blue Shield of New Jersey
and Horizon Healthcare of New Jersey, has added coverage of the
Eversense System to its Medical Policy.

Today's milestone announcements mark the company's rapid entry into the
U.S. commercial market, with the product available to U.S. patients just
six weeks since the FDA approval of the product in late June.

"Since receiving FDA approval for the Eversense System, we have
experienced tremendous support and interest from physicians and their
patients," said Tim Goodnow, President and CEO of Senseonics. "We are
thrilled that clinics and users can now benefit from Eversense, and
we're also pleased to receive our first medical policy coverage,
clearing the way so more people with diabetes can access this important
tool for helping ease the burden of managing diabetes."

The Horizon BCBSNJ coverage decision is significant not only because of
the promptness with which it followed the FDA's product approval, but
also because Horizon serves nearly 4 million covered lives primarily in
New Jersey but also in adjacent states.1

Product shipments began the last week of July to diabetes clinics across
the United States. Physicians and staff have been subsequently trained
and authorized on the Eversense System and have started their first
patients on the system.

"We are pleased to be one of the first clinics to offer Eversense to our
patients after our onboard training," said Bruce Bode, MD, FACE, Atlanta
Diabetes Associates and Clinical Associate Professor, Department of
Medicine Emory University. "I have seen the benefits of CGM in my own
practice, and it's important to me to offer the latest technology to my
patients. With an implantable long-term sensor, patients with diabetes
can have discretion when they want it, the convenience of vibratory
alerts from the transmitter, and the comfort of knowing where their
glucose is headed."

To recognize patients receiving their first Eversense sensor insertion,
Senseonics recently initiated Freedom Week, sponsored by Eversense®, to
help patients mark the day they were freed from the weekly and biweekly
self-insertions required by traditional CGM systems.

While the glucose sensors of traditional CGM systems last 7 to 14 days,
the Eversense System is the world's first and only long-term CGM system,
with a highly accurate implantable sensor that lasts up to three months.
The Eversense System also features a smart transmitter that is the first
that can be removed and re-adhered without discarding the sensor and the
first to provide discreet on-body vibratory alerts signaling high and
low glucose levels.

Patients who are interested in getting started on Eversense can sign up
at www.eversensediabetes.com/get-started-today.
Physicians interested in becoming an authorized practice can contact
844-SENSE4U (844-736-7348).

1 "The 20 Largest Health Insurance Companies,"
Nerdwallet.com, Aug. 26, 2016 (https://www.nerdwallet.com/blog/health/largest-health-insurance-companies/)

About Senseonics

Senseonics Holdings, Inc. (NYSE:SENS) is a medical technology
company focused on the design, development and commercialization of
transformative glucose monitoring products designed to help people with
diabetes confidently live their lives with ease. From its inception,
Senseonics has been advancing the integration of novel, fluorescence
sensor technology with smart wearable devices. The Eversense® CGM System
received FDA PMA approval for up to 90 days of continuous use and is
available in the United States. The Eversense® CGM XL System received CE
mark for up to 180 days of continuous use and is available in Europe.
For more information on Senseonics, please visit www.senseonics.com.

About Eversense

The Eversense System consists of a fluorescence-based sensor, a smart
transmitter worn over the sensor to facilitate data communication, and a
mobile app for displaying glucose values, trends and alerts. Light,
discreet, and comfortable to wear, the system's smart transmitter
interprets glucose data from the sensor and sends it to the system's
mobile application via Bluetooth, so patients can review their glucose
data to help them make daily diabetes decisions.

Forward Looking Statements

Any statements in this press release about future expectations, plans
and prospects for Senseonics, including statements about physician and
patient adoption of the Eversense System and other statements containing
the words "expect," "intend," "may," "will," and similar expressions,
constitute forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including: the development of the
market for CGM products generally, and Eversense in particular, people
with diabetes' perceptions of the benefits of the Eversense System,
patient use of the system, and such other factors as are set forth in
the risk factors detailed in Senseonics' Annual Report on Form 10-K for
the year ended December 31, 2017, Senseonics' Quarterly Report on Form
10-Q for the quarter ended March 31, 2018, and Senseonics' other filings
with the SEC under the heading "Risk Factors." In addition, the
forward-looking statements included in this press release represent
Senseonics' views as of the date hereof. Senseonics anticipates that
subsequent events and developments will cause Senseonics' views to
change. However, while Senseonics may elect to update these
forward-looking statements at some point in the future, Senseonics
specifically disclaims any obligation to do so except as required by
law. These forward-looking statements should not be relied upon as
representing Senseonics' views as of any date subsequent to the date
hereof.

View Comments and Join the Discussion!